Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Concerns about a potential finasteride ban in the EU, possibly affecting the US, are discussed. Users doubt a ban, citing its widespread use and suggest alternatives like minoxidil and dutasteride.

Male androgenetic alopecia is commonly treated with topical minoxidil and oral finasteride, both requiring continuous use. Other options include hair restoration surgery, dutasteride, light therapy, and camouflaging agents.

Finasteride can cause persistent side effects, including mental health issues, and it's important to consult a doctor before starting. Baseline tests for testosterone, DHT, estradiol, and semen analysis are recommended, and caution is advised for those with a history of depression, anxiety, or diabetes.

The user experienced fatigue, brain fog, and dizziness after taking Dutasteride for hair loss, suspecting it might be a side effect. They plan to consult a doctor and get blood work done, while others in the conversation discuss potential cognitive effects and compare Dutasteride to Finasteride.

Finasteride and dutasteride are still available in the EU, with a warning about potential suicidal thoughts. The benefits of these treatments are deemed greater than the risks.

Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.

Topical Clascoterone showed a 539% improvement in hair count compared to placebo, but its effectiveness and safety are debated. Users compared it to minoxidil and finasteride, with mixed opinions on its potential release in 2026 or 2027.

Finasteride and Dutasteride do not cause depression or mood disorders; hair loss itself may be a more significant factor. Some users experience side effects from Finasteride, but it is generally well-tolerated.

PP405 is a potential new hair loss treatment that works through metabolic pathways rather than hormonal ones, with an estimated market release between late 2027 and 2029. Current alternatives to finasteride include minoxidil, pyralutamide, fluridil, and RU58841, with hair transplants also being a viable option.

Finasteride and dutasteride can cause psychiatric side effects like depression and suicidal thoughts in some users, especially those with a history of mental health issues. While some users experience positive hair growth results, others face severe psychological effects, raising concerns about their safety and the need for careful monitoring.

Ritlecitinib and PP405 show promise for hair regrowth. Diagnosing the cause of hair loss is crucial before treatment.

Finasteride is debated for causing dry eyes, with some users experiencing relief after stopping it, while others find no connection. Topical treatments like dutasteride and minoxidil are suggested as alternatives, with advice to consult medical professionals.

Finasteride may cause sleep disturbances, with some users experiencing insomnia. Reducing the dosage, switching brands, or trying Dutasteride might help.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

The potential availability of a new hair loss treatment called HMI-115, which has shown promising results in experiments on monkeys but is not yet available to the public. Replies cautioned against using unproven substances from shady labs.

The post discusses a phase 2 trial for HMI-115, a hair loss treatment, in China, specifically seeking volunteers aged 18-65 with Norwood 3 vertex, 4, and 5 hair loss. The conversation includes questions about the specific recruitment criteria and how to volunteer.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

Concerns about a potential ban on finasteride and dutasteride due to side effects, with users advocating for continued access and informed choice. Alternative treatments like pyrilutamide are also mentioned.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115 release timeline is uncertain, with possible grey market availability in 2024-2025.

The conversation discusses the HMI-115 trial for hair loss, which was expected to end around July 2023 due to a late participant. Participants also mention Minoxidil, finasteride, and RU58841 as treatments.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Prolactin's role in immune system's antitumor activity raises safety concerns for HMI-115.

RU58841 is not recommended for use around children due to potential exposure risks. Alternatives like CB-03-01 might be considered, but further research is advised.

The conversation discusses the potential use of HMI 115 for hair loss and whether it could replace or be used alongside finasteride, minoxidil, and RU58841. The user is experiencing scalp inflammation and continued hair shedding despite using finasteride for 8 years.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.

The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.